Version 1.3.1 improves the local tracking experience for check-ins, dose history, weight entries, injection-site history and doctor-report preparation. Hydration now displays consistently in liters. HealthKit weight import remains optional. GLP Compass does not provide medical or dosage guidance.

GLP Compass 1.3 adds UI and UX refinements for calmer, clearer GLP-1 routine tracking. Several views, inputs and progress areas were improved so shot days, check-ins, side effects, weight entries and doctor reports are easier to capture and review. This update also continues the weekly maintenance of the study and source base used for educational medication context. Your entries stay local on your device. GLP Compass does not provide medical advice and does not replace care from a qualified clinician.

Version 1.2 brings the new research snapshot directly into the app: medication profiles, sources, and a weekly recap help you prepare your documented routine for your next doctor appointment. Retatrutide remains clearly marked as experimental. No medical advice.

What’s New in Version 1.1 • Weekly study research is now reflected more clearly in the knowledge base and App Store copy. • Updated research data for GLP-1 and incretin therapies. • Added dose profiles for tirzepatide, liraglutide, semaglutide and retatrutide. • Added Zepbound as a tirzepatide option when starting a medication profile. • Improved drug-level references and more consistent retatrutide model values. • Research summaries now show all stored dose and study facts instead of a shortened selection. Note: Content is for documentation and does not replace medical advice.